Multimodal OCS approaches WTPthreshold in UK

Multimodal OCS approaches WTPthreshold in UK PharmacoEconomics & Outcomes News 784, p24 - 12 Aug 2017 Multimodal OCS approaches WTP threshold in UK Multimodal ovarian cancer screening (OCS) in the UK appears to approach NICE willingness-to-pay (WTP) thresholds, according to findings of a study published in the British Journal of Cancer. Investigators conducted a within-trial evaluation of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) to assess the cost-effectiveness of annual transvaginal ultrasound (TSS), or annual multimodal screening (MMS) including serum CA125 levels with risk of ovarian cancer algorithm (ROCA) interpretation and second-line TSS, compared with no screening in 202 638 women 50–75 years of age, from a National Health Service (NHS) perspective over a 14-year follow- up period. A predictive model was also used to evaluate the cost effectiveness of the MMS programme compared with no screening in the UKCTOCS population over a lifetime (25-year) time horizon, and a Markov model populated with UKCTOCS data used to evaluate the cost effectiveness of MMS compared with no screening in a hypothetical cohort over a lifetime time horizon. At an assumed cost of £20 for CA125-ROCA, within- trial analysis found that MMS dominated USS (more effective and less costly). The estimated incremental cost-effectiveness ratio (ICER) for MMS compared with ** no screening was £91 452 per life-year gained (LYG). The ICER was decreased to £77 818 per LYG if the cost of CA125-ROCA was reduced to £15. Predictive analysis of UKCTOCS data extrapolated over a lifetime resulted in an estimated ICER for MMS versus TSS of £30 033 per LYG, and Markov modelling resulted an ICER of £46 922 per QALY gained. "The findings are not only highly dependent on the average effect size of the mortality reduction associated with screening but also the cost of the CA125–ROCA test, assuming this test is adopted by the NHS," said the investigators. "Whether MMS could be recommended on economic grounds would depend on the confirmation and size of the mortality benefit at the end of an ongoing follow-up of the UKCTOCS cohort," they said. * National Institute for Health and Care Excellence ** 2013/2014 British pounds Menon U, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer : 25 Jul 2017. Available from: URL: http:// 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

Multimodal OCS approaches WTPthreshold in UK

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial